Variability in antimicrobial use in pediatric ventilator-associated events.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 10 11 2018
medline: 18 12 2019
entrez: 10 11 2018
Statut: ppublish

Résumé

To assess variability in antimicrobial use and associations with infection testing in pediatric ventilator-associated events (VAEs). Descriptive retrospective cohort with nested case-control study. Pediatric intensive care units (PICUs), cardiac intensive care units (CICUs), and neonatal intensive care units (NICUs) in 6 US hospitals.PatientsChildren≤18 years ventilated for≥1 calendar day. We identified patients with pediatric ventilator-associated conditions (VACs), pediatric VACs with antimicrobial use for≥4 days (AVACs), and possible ventilator-associated pneumonia (PVAP, defined as pediatric AVAC with a positive respiratory diagnostic test) according to previously proposed criteria. Among 9,025 ventilated children, we identified 192 VAC cases, 43 in CICUs, 70 in PICUs, and 79 in NICUs. AVAC criteria were met in 79 VAC cases (41%) (58% CICU; 51% PICU; and 23% NICU), and varied by hospital (CICU, 20-67%; PICU, 0-70%; and NICU, 0-43%). Type and duration of AVAC antimicrobials varied by ICU type. AVAC cases in CICUs and PICUs received broad-spectrum antimicrobials more often than those in NICUs. Among AVAC cases, 39% had respiratory infection diagnostic testing performed; PVAP was identified in 15 VAC cases. Also, among AVAC cases, 73% had no associated positive respiratory or nonrespiratory diagnostic test. Antimicrobial use is common in pediatric VAC, with variability in spectrum and duration of antimicrobials within hospitals and across ICU types, while PVAP is uncommon. Prolonged antimicrobial use despite low rates of PVAP or positive laboratory testing for infection suggests that AVAC may provide a lever for antimicrobial stewardship programs to improve utilization.

Identifiants

pubmed: 30409233
pii: S0899823X18002647
doi: 10.1017/ice.2018.264
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-39

Subventions

Organisme : AHRQ HHS
ID : R18 HS021636
Pays : United States

Auteurs

Manjiree V Karandikar (MV)

1Department of Population Medicine,Harvard Pilgrim Health Care Institute and Harvard Medical School,Boston,Massachusetts.

Susan E Coffin (SE)

3Children's Hospital of Philadelphia and Perelman School of Medicine at University of Pennsylvania,Philadelphia,Pennsylvania.

Gregory P Priebe (GP)

4Division of Critical Care Medicine,Department of Anesthesiology,Critical Care and Pain Medicine,Boston Children's Hospital,Boston,Massachusetts.

Thomas J Sandora (TJ)

5Division of Infectious Diseases,Department of Medicine,Boston Children's Hospital,Boston,Massachusetts.

Latania K Logan (LK)

6Section of Infectious Diseases,Department of Pediatrics,Rush University Medical Center,Rush Medical College,Chicago,Illinois.

Gitte Y Larsen (GY)

7Division of Critical Care Medicine,Department of Pediatrics,Intermountain Primary Children's Hospital and University of Utah,Salt Lake City,Utah.

Philip Toltzis (P)

8Division of Pediatric Critical Care,Department of Pediatrics,Rainbow Babies and Children's Hospital,Cleveland,Ohio.

James E Gray (JE)

9Department of Neonatology,Beth Israel Deaconess Medical Center,Boston,Massachusetts.

Michael Klompas (M)

1Department of Population Medicine,Harvard Pilgrim Health Care Institute and Harvard Medical School,Boston,Massachusetts.

Julia S Sammons (JS)

3Children's Hospital of Philadelphia and Perelman School of Medicine at University of Pennsylvania,Philadelphia,Pennsylvania.

Marvin B Harper (MB)

5Division of Infectious Diseases,Department of Medicine,Boston Children's Hospital,Boston,Massachusetts.

Kelly Horan (K)

1Department of Population Medicine,Harvard Pilgrim Health Care Institute and Harvard Medical School,Boston,Massachusetts.

Matthew Lakoma (M)

1Department of Population Medicine,Harvard Pilgrim Health Care Institute and Harvard Medical School,Boston,Massachusetts.

Noelle M Cocoros (NM)

1Department of Population Medicine,Harvard Pilgrim Health Care Institute and Harvard Medical School,Boston,Massachusetts.

Grace M Lee (GM)

1Department of Population Medicine,Harvard Pilgrim Health Care Institute and Harvard Medical School,Boston,Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH